For people living with polycythemia vera, treatment has long meant returning to a clinic to have blood physically removed, sometimes every few weeks, indefinitely. A newly approved weekly injection reduced that requirement for most patients in its pivotal trial.
The Food and Drug Administration approved Mimrylo for polycythemia vera, known generically as rusfertide, for the treatment of erythrocytosis in adults with the disease. It is the first approved treatment for the condition that mimics hepcidin, the hormone that naturally regulates iron in the body.
Polycythemia vera is a chronic blood cancer in which the bone marrow produces too many red blood cells. The excess thickens the blood and raises the risk of clots, stroke and heart attack. Keeping hematocrit below 45 percent is the central treatment goal. Takeda, which announced the approval alongside the agency, says the disease affects roughly 90,000 people in the United States.
The Burden This Drug Is Designed to Reduce
Therapeutic phlebotomy is effective, and it is also demanding. A patient may need blood removed every few weeks, each visit requiring travel, time away from work, and a needle. Repeated phlebotomy also deepens iron deficiency, which contributes to the fatigue many patients describe as the hardest part of living with the disease.
Rusfertide takes a different route. By mimicking hepcidin, it limits the iron available for making new red blood cells, addressing the underlying iron dysregulation rather than removing the product after the fact. It is given as a subcutaneous injection once weekly, and the trial protocol had patients self-administering it.
For a household, the practical translation is a possible shift from recurring clinic appointments to a weekly injection that may be given at home. That changes caregiving logistics, work absence, and travel burden, particularly for patients in rural areas who drive substantial distances for each session.
The Trial Numbers and Their Limits
The approval rests on VERIFY, a multicenter, randomized, placebo-controlled phase 3 study of 293 adults with polycythemia vera who still required frequent phlebotomies despite ongoing standard-of-care therapy. Participants were randomized one-to-one and treated over 32 weeks, starting at 19 mg weekly with dose titration aimed at keeping hematocrit below 45 percent.
The primary endpoint was the proportion of patients who did not meet criteria for phlebotomy during weeks 20 through 32. On that measure, 76.9 percent of patients receiving rusfertide responded, compared with 32.9 percent on placebo. The trial was presented in a plenary session at the ASCO annual meeting, an unusual placement for a study in this disease.
Several limitations belong in the same paragraph as the headline number, not buried below it. The study measured phlebotomy avoidance, hematocrit control and symptom scores, not survival, and not rates of clot, stroke or heart attack. Whether reduced phlebotomy translates into fewer cardiovascular events remains unestablished. The trial enrolled patients whose disease was inadequately controlled on existing therapy, so the result may not generalize to newly diagnosed patients or those already well controlled. VERIFY is ongoing, designed to run 156 weeks, and all participants have now entered open-label phases.
According to the prescribing information summarized by Takeda, the most common adverse reactions were injection site reactions, at 56 percent, and anemia, at 16 percent. The label also carries warnings for new or worsening thrombocytosis, which can require blood count monitoring every two to four weeks, for injection site reactions including severe ones, and for possible fetal harm based on animal studies. Longer follow-up presented at ASH reported that 61.9 percent of patients who continued on the drug remained free of phlebotomy eligibility through week 52.
Rusfertide was discovered by Protagonist Therapeutics, which led development through phase 3. Takeda now holds exclusive global development and commercialization rights. Readers should weigh company-reported figures with that commercial interest in view.
Cost and Access Are the Open Questions
Neither the FDA announcement nor the company release stated a list price. For a weekly injectable in a rare disease, cost is likely to be a central determinant of who actually gets it, and coverage decisions typically follow approval by weeks to months rather than arriving with it.
Patients considering the drug have concrete questions to bring to a hematologist. Whether their disease pattern matches the trial population. Whether their insurer has issued a coverage policy. Whether prior authorization will require documented phlebotomy frequency. Whether a manufacturer patient assistance program exists. And whether self-injection at home is appropriate for them.
No one should stop or change an existing polycythemia vera treatment on the basis of an approval announcement. Hydroxyurea, interferon and ruxolitinib remain standard options, and rusfertide was studied as an addition to standard care rather than a replacement for it.
The Next Signals Worth Watching
Takeda said additional VERIFY findings will be presented at upcoming medical conferences and that it is working with regulators outside the United States. The extension phases should eventually produce longer-term safety data and, potentially, information on cardiovascular outcomes that the 32-week analysis could not address.
Also unresolved is whether treatment guidelines will incorporate the drug, and where it will sit in the sequence relative to existing therapies. Guideline committees generally move after approval rather than with it, and hematologists will want longer follow-up before changing how they sequence therapy.
The distribution question is also open. Specialty products are frequently limited to particular pharmacy networks, which can mean a patient's usual pharmacy cannot fill the prescription and the medication ships to the home instead. Patients should ask where the drug will come from and how it must be stored before the first shipment arrives, and can review the full prescribing information with their clinician.
Polycythemia vera symptoms can include fatigue, itching that worsens after a warm shower, difficulty concentrating, and night sweats. Anyone with sudden chest pain, shortness of breath, weakness on one side, difficulty speaking, or swelling and pain in one leg should seek emergency care, since clotting complications are the principal danger of the disease.
Key Questions Answered
What did the FDA approve? Mimrylo, generically rusfertide, for the treatment of erythrocytosis in adults with polycythemia vera. It is a once-weekly subcutaneous injection.
How does it work? It mimics hepcidin, the hormone that regulates iron, limiting the iron available for red blood cell production so hematocrit can be controlled.
What did the trial show? In 293 adults, 76.9 percent on rusfertide met the response definition during weeks 20 to 32, compared with 32.9 percent on placebo.
What did the trial not show? It did not measure survival or rates of clot, stroke, and heart attack. Whether fewer phlebotomies translate into fewer cardiovascular events is unestablished.
What are the side effects? Injection site reactions in 56 percent and anemia in 16 percent were the most common. The label also warns about rising platelet counts and possible fetal harm.
Does this replace existing treatment? No. It was studied as an addition to standard-of-care therapy in patients still requiring frequent phlebotomy, not as a replacement.
How much will it cost? No list price was announced. Patients should ask their hematologist about coverage, prior authorization requirements, and manufacturer assistance programs.
